Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.37 |
| ▸ | ATF1 | P18846 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30422832 | 1.00 | MAPT (0.41) | MAPTPOLBHTTPTPN11LCK | |
| SCHEMBL31485467 | 0.94 | HSD11B1 (0.40) | MAPTPOLBHTTPTPN11IRAK4 | |
| SCHEMBL31148446 | 0.91 | IRAK4 (0.38) | MAPTHTTPTPN11IRAK4ATF1 | |
| SCHEMBL25437177 | 0.91 | IRAK4 (0.38) | MAPTHTTPTPN11IRAK4ATF1 | |
| SCHEMBL31148463 | 0.90 | IRAK4 (0.39) | MAPTPOLBHTTPTPN11IRAK4 | |
| SCHEMBL30422535 | 0.90 | HTT (0.49) | MAPTPOLBHTTPTPN11 | |
| Hydrochloric Acid SCHEMBL31148450 | 0.89 | PTPN11 (0.47) | MAPTPOLBPTPN11 | |
| SCHEMBL25210578 | 0.89 | PTPN11 (0.45) | MAPTPOLBPTPN11ATF1NFKB1 | |
| Formic Acid SCHEMBL31148383 | 0.89 | MAPT (0.40) | MAPTPOLBPTPN11ATF1NFKB1 | |
| Formic Acid SCHEMBL31148454 | 0.88 | HTT (0.35) | HTTPTPN11IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122192-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| WO-2023102231-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122192-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | RTCB, NSUN2, PRPF19 | MAPT 4668/4885POLB 276/4885HTT 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.